KRAS and osteosarcoma: Osteosarcoma-derived CTCs were assayed for MDM-2 and KRAS amplification, highlighting a difference between patients diagnosed with metastasis in the lung or localized osteosarcoma [192,193], thus predicting the onset of metastatic lesions at distant sites and potentially the therapeutic efficacy of drugs [92].